Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy.
To determine the incidence of B19 infection in patients with AIDS who were being treated with dideoxyinosine, serial sera (n = 28) taken over a 2-year period from 14 individuals were analyzed with respect to anti-B19 serology and the presence of B19 DNA. All 14 individuals were anti-B19 IgM negative. Nine of 14 had B19 viremia by Southern analysis of polymerase chain reaction product. Five of 9 with B19 viremia had > or = 1 anti-B19 IgG-positive sample; none of 5 without viremia had anti-B19 IgG. Four of 9 viremic individuals had serially positive samples. All 4 had severe anemia (hemoglobin < 8.5 g/dL) while taking zidovudine. A fifth individual whose severe anemia resolved after zidovudine was discontinued did not have B19 viremia. Therefore, a significant proportion of this group of patients with AIDS who developed severe anemia while receiving zidovudine had persistent B19 infection. These results suggest that B19 infection should be considered in anemic patients with AIDS.
Naides
S J
SJ
Dept. of Internal Medicine, University of Iowa College of Medicine, Iowa City 52242.
Howard
E J
EJ
Swack
N S
NS
True
C A
CA
Stapleton
J T
JT
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology* / Q000382:microbiology; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D016049:Didanosine / Q000627:therapeutic use; D016731:Erythema Infectiosum / Q000150:complications / Q000453:epidemiology*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016732:Parvovirus B19, Human / Q000276:immunology; D015215:Zidovudine / Q000627:therapeutic use*
D000914:Antibodies, Viral; D015215:Zidovudine; D016049:Didanosine